FDA Considers Availability of Masked and De-Identified Data

The FDA is considering making more masked and de-identified safety and efficacy data from clinical and preclinical trials available to boost opportunities for innovative drug development. Saying such data has previously been used to address key hurdles in medical product development, the agency is seeking public and industry stakeholder comments on the subject.
Washington Drug Letter